CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies

CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news